Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Significance of a coronary-artery with thrombolysis in myocardial-infarction grade-2 flow patency (outcome in the thrombolysis and angioplasty in myocardial-infarction trials)

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Lincoff, A. M.
  • Topol, Eric
  • Califf, R. M.
  • Sigmon, K. N.
  • Lee, K. L.
  • Ohman, E. M.
  • Rosenschein, U.
  • Ellis, S. G.

publication date

  • May 1995

journal

  • American Journal of Cardiology  Journal

abstract

  • To determine whether pharmacologic reperfusion to Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow during acute myocardial infarction confers the same clinical benefit as restoration of TIMI 3 flow, in-hospital clinical and angiographic outcomes in 1,229 patients prospectively enrolled in the Thrombolysis and Angioplasty in Myocardial Infarction trials were analyzed. Patients were treated with intravenous tissue plasminogen activator or urokinase, or both. Angiography of the infarct-related artery 90 minutes after initiation of thrombolytic therapy demonstrated TIMI grades 0, 1, 2, or 3 flow in 20%, 7%, 17%, and 55% of vessels, respectively. Rescue or adjunctive coronary angioplasty was performed in 80%, 27%, and 16% of patients with TIMI 0/1, 2, or 3 flow, respectively. Predischarge angiography was performed in 963 patients. A significant gradient of increasing mortality was seen in patients with lower TIMI flow (4.3%, 6.1%, and 10.1% with TIMI 3, 2, and 0/1 flow, respectively, p = 0.002). The incidence of congestive heart failure and recurrent ischemia was significantly higher in patients with TIMI 2 than with TIMI 3 perfusion (26% vs 19% for heart failure, p = 0.03; 23% vs 17% for recurrent ischemia, p = 0.05). Acute left ventricular ejection fraction and infarct zone regional wall motion were also significantly improved in patients with TIMI 3 than with TIMI 2 flow, with trends toward better improvement in global and regional function in the TIMI 3 group. These findings were not affected by the use of acute coronary angioplasty.(ABSTRACT TRUNCATED AT 250 WORDS)

subject areas

  • Angioplasty, Balloon, Coronary
  • Coronary Angiography
  • Coronary Artery Bypass
  • Coronary Circulation
  • Coronary Disease
  • Female
  • Heart Failure
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Prospective Studies
  • Recurrence
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator
  • Vascular Patency
  • Ventricular Function, Left
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0002-9149

Digital Object Identifier (DOI)

  • 10.1016/s0002-9149(99)80678-x

PubMed ID

  • 7732992
scroll to property group menus

Additional Document Info

start page

  • 871

end page

  • 876

volume

  • 75

issue

  • 14

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support